A Study to Explore the Role of Gut Flora in COVID-19 Infection

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorProgenaBiome

About this trial

This study seeks to determine whether the virus which causes COVID-19, SARS-CoV-2, is shed in the stools of patients who are infected.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study

Male or female of 18 years of age or older

Diagnosis of COVID-19 infection by RT- PCR within 1 week of Screening

Disqualifiers

Refusal to sign informed consent form

History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.

Postoperative stoma, ostomy, or ileoanal pouch

Treatment with total parenteral nutrition

Trial population

Adults 18 and older

Trial design

Design model

Other

Time perspective

Other

Treatments tested in this trial

  • There is no intervention in this study

    Other intervention

    There is no intervention in this study

Treatment groups

250 Participants
are divided into 1 treatment group
Group A: General Population1 intervention

Trial outcomes

Primary outcomes

1

Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing

Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized among specific gastrointestinal disease types.

Time frame
One year

Secondary outcomes

1

Validation of Sequencing Methods

To validate the methods used to sequence samples

Time frame
One year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.